-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Regulations of the People's Republic of China on the Management of Human Genetic Resources, issued in 2019, explicitly encourage international cooperation in the use of human genetic resources.
the adoption of this clinical trial-related form review, opened an important course stone in Lingbei, and is the first time Lingbei China as an applicant submitted a completed application for international cooperation in human genetic resources.
It breaks the previous restrictions on human genetic resources applications to rely on research centers, is the embodiment of Lingbei's commitment to strengthening China's new drug development capabilities, for accelerating the launch of innovative drugs in China clinical trials, as well as the clinical development of subsequent product pipelines laid a foundation, providing valuable experience.
clinical trial is part of a phase III international multicenter clinical research project with the migraine drug Vyepti ® registered in China.
Yu Shengyuan, an authoritative expert in the field of migraines in China and a leading researcher on the project, will lead the project in clinical studies at 30 institutions across the country.
As a preventive treatment for adult migraines, Vyepti® is the first and only intravenous treatment for migraine prevention that will provide patients with effective and safe treatment, with only four intravenous injections per year.
February 21 this year, Vyepti's ® approved by the U.S. Food and Drug Administration (FDA) and is now available in the United States.
On August 3rd, Lingbei China, in close cooperation with the research and development team at Lingbei's headquarters, submitted a clinical trial application to the Drug Review Center of the State Drug Administration and was approved on November 5th, meaning that the new drug is likely to complete clinical trials in the next few years and officially enter the Chinese market, bringing good news to more migraine sufferers.
a hundred-year-old pharmaceutical company, Lingbei has unique expertise in the field of brain disease.
Since entering China in the late 1990s through partnerships with partners, Lingbei's six products have covered treatment areas such as Alzheimer's disease, depression and Parkinson's disease, five of which have been included in the national health insurance list, significantly improving patient drug access.
Di Carlo, general manager of Lingbei China, stressed that Lingbei will continue to be firmly committed to China and Lingbei's commitment to Chinese patients will not change.
goal is to help every patient recover their brain health.
face of the new development pattern, Lingbei will do a good job of resource arrangements to seize the opportunities in the Chinese market.
based on its research and development experience and market base in China, Lingbei will continue to work with the government and local partners to continuously provide patients with high-quality drug options and reduce the burden of brain disease.
in the field of deep-ploughed brain disease for many years, Lingbei has also been committed to the knowledge of brain disease education.
In China, Lingbei has jointly launched a number of projects, including international expert academic conferences and lectures, patient education, public science and so on, as well as a professional medical and health professionals for Lingbei College, spiritual gods and other professional knowledge base and digital education platform.
recently, Lingbei China's "2019 Green Ribbon Science Event" won the Bronze Award in the Public Health and Medical Health Communication Category in the 16th China Public Relations Industry Best Case Competition hosted by the China International Public Relations Association.
this is the third award won by Lingbei China's "Green Ribbon Series Of Science and Technology".
the future, Lingbei will continue to focus on the disease science in its field of focus, with practical actions to help raise awareness of mental health and improve the quality of life of patients.
lingbei can climb the peak in the field of research and development and products, from its focus on innovation, flexible and efficient corporate culture.
, Lingbei continues to strengthen the organization, pay more attention to the internal training and development of talent, to create an excellent management team, a strong research and development team and a dynamic sales team.
also encourages flexible and efficient working methods and establishes multi-dimensional promotion mechanisms and flexible benefits that offer unlimited possibilities for employee development.
in this year's Chinese Chinese Development Community) 5th National Learning Design Competition, Lingbei China's "Year of Excellence in Performance Coaching" project won the gold medal, and its "Internet plus hybrid learning" project won the silver medal.
"Spark In-House Trainer Project" won the 11th Chinese the "Best Learning Project" for the development of the "Best Learning Project".
is small, but dynamic, fast paced, but very respectful of equality between people, willing to provide employees with opportunities to expand the field of work.
humane Lingbei in China unremitting efforts, continuous innovation, is committed to helping more patients improve brain health, become a better self.
。